



March 10, 2016

TransEnterix to Exhibit at Society of American Gastrointestinal and Endoscopic Surgeons Annual Meeting

Highlighting two robotic surgery platforms at major general surgery meeting

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT: TRXC) today announced that it will exhibit at the 2016 Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) Annual Meeting. The Company's multi-port robotic platform, the ALF-X[®] System, will be exhibited alongside the Company's single-port robotic platform, the SurgiBot[™] System. SAGES will be held March 16-19, 2016 at the Hynes Convention Center in Boston, Massachusetts. This represents the first major medical meeting at which TransEnterix will display both of its robotic platforms.

"SAGES is an important gathering of the leaders of minimally invasive surgery, and we are pleased to display our two new robotic surgery platforms, which will continue to advance the field," said Todd M. Pope, President and CEO of TransEnterix. "Robotics is forecasted to grow rapidly in the coming years and these two new technologies represent the first anticipated new entrants to help accelerate the adoption of robotic surgery globally."

A demonstration and Q&A with Company management will be held for investors and attending media at 10am on Friday, March 18, 2016 at the TransEnterix booth (#1209).

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the development and commercialization of the SurgiBot[™] System, a single-port, robotically enhanced laparoscopic surgical platform, and the ALF-X[®] System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye tracking camera control. The SurgiBot System is not available for sale in the U.S. The ALF-X has been granted a CE Mark, and is commercially available in Europe, but is not available for sale in the U.S. For more information, visit TransEnterix online at www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the ALF-X[®] System, the SurgiBot[™] System and our current regulatory and commercialization plans for these products. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations, including whether we will be able to successfully commercialize the SurgiBot System and the ALF-X System; whether our two robotic surgery platforms will continue to advance the field and whether the technologies will help accelerate the adoption of robotic surgery globally. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20160310006413/en/>

For TransEnterix, Inc.

Investor Contact:

Mark Klausner, 443-213-0501

invest@transenterix.com

or

Media Contact:

Joanna Rice, 951-751-1858

joanna@greymattermarketing.com

Source: TransEnterix, Inc.

News Provided by Acquire Media